Skip to content
CancerIndex

Publication

Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer.

Authors not recorded

Cancer Discov2013PMID 23729478PMC4078408stubpubmedProvenance
Source
PubMed
Retrieved
Sep 8, 2026
Layer
normalized (units and labels harmonized; values unchanged)
Run
ING-CIVIC-20260908-000001
Published

Abstract

Abstract (excerpt)

Only the opening of the abstract is shown; abstract text may carry publisher copyright.

Data not yet available

No abstract stored. Read on PubMed

Linked entities

Linked entities (9)

How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.

Validated 9

Curated evidence

Evidence citing this paper (2)

civicProvenance
Source
CIViC — Clinical Interpretation of Variants in Cancer
Dataset
CIViC evidence items
Version
civic-2026-09-08
Retrieved
Sep 8, 2026
Layer
normalized (units and labels harmonized; values unchanged)
Evidence
expert curation
License
CC0 1.0
PMID
23729478
Run
ING-CIVIC-20260908-000001
Open at source
CuratedShowing 1–2 of 2 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.
TherapyCancerTypeLevelDirection · significanceRating (1–5)StatusEvidenceSource
KRAS Mutation + MET AmplificationMETKRAS2
Cetuximab + CrizotinibCombinationMalignant Colorectal NeoplasmCURATED_BROADERPredictiveDSupports Sensitivity Response3accepted
EID1979

Functional studies show that MET activation confers resistance to anti-EGFR therapy both in vitro and in vivo. Notably, in patient-derived colorectal cancer xenografts, MET amplification correlated wi… (full text at CIViC)

PMID 23729478 · Bardelli et al., 2013 · Open in CIViC

civic
Cetuximab/Irinotecan Regimen + PanitumumabSubstitutesMalignant Colorectal NeoplasmCURATED_BROADERPredictiveCSupports Resistance3accepted
EID1971

7 patients with acquired resistance to EGFR inhibitors were analyzed in this study. Of these, 4 did not develop KRAS mutations. Post- and Pre-Treatment tissued was available of three patients and MET … (full text at CIViC)

PMID 23729478 · Bardelli et al., 2013 · Open in CIViC

civic